Agios Pharmaceuticals, Inc. (AGIO)

$29.38

+0.66 (+2.30%)
Rating:
Recommendation:
Neutral
Symbol AGIO
Price $29.38
Beta 1.178
Volume Avg. 0.75M
Market Cap 1.611B
Shares () -
52 Week Range 16.75-50.98
1y Target Est -
DCF Unlevered AGIO DCF ->
DCF Levered AGIO LDCF ->
ROE -21.95% Sell
ROA -21.98% Sell
Operating Margin -
Debt / Equity 11.42% Neutral
P/E -
P/B 1.43 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AGIO news


Dr. Jacqualyn Fouse
Healthcare
Biotechnology
NASDAQ Global Select

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.